MYGN Quote, Financials, Valuation and Earnings

Intuitive Surgical, Inc. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 27.89%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Myriad Genetics, Inc. has a consensus price target of $8.12, signalling upside risk potential of 46.57%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 20.54%. Given that Myriad Genetics, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Myriad Genetics, Inc. is more attractive than Intuitive Surgical, Inc..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.11% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 64.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.62x versus 18.29x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neogen Corp. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of -7.09%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Neogen Corp.'s return on equity of -25.93%.

Myriad Genetics, Inc. has a consensus price target of $8.12, signalling upside risk potential of 46.57%. On the other hand Neogen Corp. has an analysts' consensus of $11.67 which suggests that it could grow by 14.27%. Given that Myriad Genetics, Inc. has higher upside potential than Neogen Corp., analysts believe Myriad Genetics, Inc. is more attractive than Neogen Corp..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.11% more volatile than S&P 500. In comparison Neogen Corp. has a beta of 1.956, suggesting its more volatile than the S&P 500 by 95.564%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neogen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Neogen Corp. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than Neogen Corp. quarterly revenues of $224.7M. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Neogen Corp.'s net income of -$15.9M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Neogen Corp.'s PE ratio is 2,124.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.62x versus 2.52x for Neogen Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 12.4%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Insulet Corp.'s return on equity of 18.92%.

Myriad Genetics, Inc. has a consensus price target of $8.12, signalling upside risk potential of 46.57%. On the other hand Insulet Corp. has an analysts' consensus of $370.44 which suggests that it could grow by 45.21%. Given that Myriad Genetics, Inc. has higher upside potential than Insulet Corp., analysts believe Myriad Genetics, Inc. is more attractive than Insulet Corp..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.11% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.400, suggesting its more volatile than the S&P 500 by 39.975%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Insulet Corp.'s net income of $87.6M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Insulet Corp.'s PE ratio is 74.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.62x versus 7.32x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 17.41%. Myriad Genetics, Inc.'s return on equity of -69.09% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Myriad Genetics, Inc. has a consensus price target of $8.12, signalling upside risk potential of 46.57%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 48.6%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Myriad Genetics, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Myriad Genetics, Inc..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.11% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.37% to investors and pays a quarterly dividend of $0.22 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Myriad Genetics, Inc.'s net income of -$27.4M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 34.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.62x versus 5.62x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.